113 related articles for article (PubMed ID: 10099929)
1. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
2. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
3. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
Caro J; Klittich W; McGuire A; Ford I; Pettitt D; Norrie J; Shepherd J
Eur Heart J; 1999 Feb; 20(4):263-8. PubMed ID: 10099920
[TBL] [Abstract][Full Text] [Related]
4. More on pravastatin and coronary disease.
Grundy SM
N Engl J Med; 1996 Oct; 335(16):1239-40. PubMed ID: 8999328
[No Abstract] [Full Text] [Related]
5. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
7. [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Berger K; Klose G; Szucs TD
Med Klin (Munich); 1997 Jun; 92(6):363-9. PubMed ID: 9297070
[TBL] [Abstract][Full Text] [Related]
8. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.
Ito MK; Shabetai R
Am J Cardiol; 1997 Sep; 80(6):799-802. PubMed ID: 9315597
[TBL] [Abstract][Full Text] [Related]
10. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
Sato S; Matsushita Y; Kobayashi T; Awata N
Nihon Eiseigaku Zasshi; 2004 Jul; 59(3):335-41. PubMed ID: 15359898
[TBL] [Abstract][Full Text] [Related]
14. Prevention of coronary heart disease with pravastatin.
Rogers S
N Engl J Med; 1996 May; 334(20):1333; author reply 1334-5. PubMed ID: 8609956
[No Abstract] [Full Text] [Related]
15. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
16. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Glasziou PP; Simes RJ; Hall J; Donaldson C
Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
[TBL] [Abstract][Full Text] [Related]
17. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin and coronary heart disease.
Bloom JM
N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831
[No Abstract] [Full Text] [Related]
19. Coronary risk assessment methods and cholesterol lowering.
Smith GD; Ebrahim S
Lancet; 1999 Mar; 353(9158):1097. PubMed ID: 10199372
[No Abstract] [Full Text] [Related]
20. [Be careful about pseudo-information on cost-effectiveness].
Lindberg M
Lakartidningen; 1998 Jan; 95(3):144. PubMed ID: 9467283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
